1. Home
  2. ONEG vs CALC Comparison

ONEG vs CALC Comparison

Compare ONEG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

N/A

Current Price

$0.97

Market Cap

16.5M

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.59

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
CALC
Founded
2021
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5M
19.1M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
ONEG
CALC
Price
$0.97
$1.59
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $50.00
AVG Volume (30 Days)
35.1K
★ 62.0K
Earning Date
07-23-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.44
52 Week High
$14.95
$7.20

Technical Indicators

Market Signals
Indicator
ONEG
CALC
Relative Strength Index (RSI) 22.61 46.84
Support Level $0.85 $0.51
Resistance Level $0.97 $2.31
Average True Range (ATR) 0.03 0.12
MACD -0.00 -0.08
Stochastic Oscillator 32.18 3.85

Price Performance

Historical Comparison
ONEG
CALC

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction projects include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: